PEGINTRON Poster Presentations
Sustained virologic response after peginterferon alfa-2b and ribavirin treatment predicts long-term clearance of HCV at 5-year follow-up. Manns, M. et al.
Platelet count predicts sustained viral response (SVR) in the retreatment of previous interferon/ribavirin non-responders (NR): results from the EPIC3 program. Poynard, T. et. al.
Impact of viral load and cirrhosis on treatment outcome in HCV genotype 3-infected patients: results of the Canadian POWeR program. Marotta, P.J. et al.
The EASL Inaugural Poster Session and Welcome Reception will take place in the Poster Hall on Thursday, April 24, beginning at 7:00 p.m.
Boceprevir Oral Presentations
Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. Schiff, E. et al. General Session 3, Saturday, April 26, 9:30 a.m., Hall A.
Interim results from HCV SPRINT-1: RVR/EVR from Phase II study of boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. Kwo, P. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 5:45 p.m. Hall A.
Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034). Susser, S. et al. Parallel Session 7, Friday April 25, 5:00 p.m., Hall 000.
Schering-Plough Media/Advocate Roundtable
Treating HCV Now and in the Future -- the Right Therapy for the Right Patient: What are the implications of the IDEAL study? Saturday, April 26, 6:30-8:00 p.m., Milan Convention Center, Room 4.
An expert panel of leading clinical investigators, key opinion leaders
and advocates will lead a roundtable discussion following a review of the
results of the IDEAL study and other recent clinical studies to address the
implications for current therapy and
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved